Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine.
covid 19
covid 19 vaccine complication
covid- 19 case report
covid-19 vaccine
morbilliform
morbilliform drug eruption
oxford-astrazeneca vaccine
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
29
04
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Morbilliform eruption typically implies a maculopapular rash of acute onset. Drugs are the predominant cause of this cutaneous reaction in adults, followed by infectious exanthems and some rheumatological diseases. In this article, we report on the clinical and histopathological features of generalized pruritic morbilliform eruption in a 28-year-old female following her second dose of Oxford/AstraZeneca COVID-19 vaccine. The reaction started 12 hours after receiving the vaccine with no other identifiable cause. The patient had no improvement with IV antihistamine received in the emergency department. Afterward, she showed marked improvement after receiving a short course of oral corticosteroids along with topical corticosteroid and oral antihistamine. To the best of our knowledge, we hypothesize that the basic immunological mechanism is the cause behind COVID-19-vaccine-related morbilliform eruption. Therefore, physicians should be aware of the possible adverse reactions associated with COVID-19 vaccines, such as morbilliform eruptions and other cutaneous manifestations.
Identifiants
pubmed: 35663693
doi: 10.7759/cureus.24649
pmc: PMC9156371
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e24649Informations de copyright
Copyright © 2022, Alhammad et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Vaccines (Basel). 2021 Apr 16;9(4):
pubmed: 33923530
Dermatol Ther. 2021 Sep;34(5):e15085
pubmed: 34350668
Dermatol Ther. 2021 Nov;34(6):e15129
pubmed: 34533265
Hum Pathol. 2021 Jan;107:39-45
pubmed: 33161030
Br J Dermatol. 2022 Jan;186(1):142-152
pubmed: 34254291
Clin Dermatol. 2021 May-Jun;39(3):523-531
pubmed: 34518015
J Eur Acad Dermatol Venereol. 2022 Jan;36(1):e16-e18
pubmed: 34547126
J Am Acad Dermatol. 1985 Aug;13(2 Pt 1):167-79
pubmed: 2931455